Generic Name/API: lamivudine

Manufacturer: GSK

Dosage Forms & Strength & Pack Size:
Tablet, 100 mg, 28’s

Keep this medicine out of the sight and reach of children.
Don’t take this medicine after the expiry date shown on the carton and blister.
Don’t store above 30 °C.
Do not throw away any medicines in your wastewater or household rubbish. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help to protect the environment.


ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.

What is ZOLINZA?
ZOLINZA is a prescription medicine for a type of cancer called cutaneous T-cell lymphoma (CTCL), which is a blood cell cancer that affects your skin. ZOLINZA is used when your CTCL gets worse, does not go away, or comes back after you have taken other medicines.

Thromboembolism: Monitor for pertinent signs and symptoms of pulmonary embolism and deep vein
thrombosis. (5.1)
Myelosuppression: Thrombocytopenia and anemia may require dose modification or discontinuation.
Monitor blood counts every 2 weeks during the first 2 months of therapy and monthly thereafter. (2.2,
5.2, 6)
Gastrointestinal Toxicity: Nausea, vomiting and diarrhea; patients may require antiemetics,
antidiarrheals, and fluid and electrolyte replacement to prevent dehydration. (5.3, 6)
Hyperglycemia: Monitor blood glucose every 2 weeks during the first 2 months of therapy and monthly
thereafter. (5.4)
Clinical Chemistry Abnormalities: Measure and correct abnormal electrolytes, creatinine, magnesium
and calcium at baseline. Monitor every 2 weeks during the first 2 months of therapy and at least
monthly during treatment. (5.5)
Severe Thrombocytopenia with Concomitant Use of other HDAC Inhibitors: Severe thrombocytopenia
with gastrointestinal bleeding has been reported with concomitant use of ZOLINZA and other HDAC
inhibitors (e.g., valproic acid). Monitor platelet counts more frequently. (5.6, 7.2)
Embryo-Fetal Toxicity: Fetal harm can occur when administered to a pregnant woman. Women should
be apprised of the potential harm to the fetus. (5.7)

Scroll to Top